Brian Marckx, CFA
Long/short equity

Put Corgenix On Your Radar

Corgenix Medical (OTCQB:CONX) reported financial results for the fiscal second quarter ending December 31, 2013. Results were largely in-line but slightly better than our estimates. Particularly noteworthy was relative q-to-q strength in international sales. While international sales fell 18% on a y-o-y basis, they showed a nice rebound sequentially, jumping more than 100% from Q1. As we noted in our previous update, we had expected international sales to firm up throughout the remainder of fiscal 2014.

CONX continues to grow both the top-line as well as margins with gross margins continuing to exhibit greater strength with a higher volume of sales. Similar to the previous four quarters, gross margin was relatively strong and better than our estimate. Management's

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details